{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:05:55Z","timestamp":1788923155819,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["neuromodulationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromodulation: Technology at the Neural Interface"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1111\/j.1525-1403.2006.00055.x","type":"journal-article","created":{"date-parts":[[2006,4,11]],"date-time":"2006-04-11T12:45:30Z","timestamp":1144759530000},"page":"75-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":178,"title":["Intrathecal Ziconotide in the Treatment of Chronic Nonmalignant Pain: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial"],"prefix":"10.1016","volume":"9","author":[{"given":"Mark S.","family":"Wallace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Charapata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Byas-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Staats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1525-1403.2006.00055.x_bib1","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.4071055","article-title":"Peptide neurotoxins from fish-hunting cone snails","volume":"230","author":"Olivera","year":"1985","journal-title":"Science"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0304-3959(94)00094-U","article-title":"Effect of continuous intrathecal infusion of omega-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats","volume":"60","author":"Malmberg","year":"1995","journal-title":"Pain"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib3","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0022-3565(25)21283-6","article-title":"Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain","volume":"279","author":"Bowersox","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib4","first-page":"25","article-title":"Neuronal N-type calcium channels: new prospect in pain therapy","volume":"5","author":"Mathur","year":"1998","journal-title":"Pharm News"},{"issue":"Suppl. 1","key":"10.1111\/j.1525-1403.2006.00055.x_bib5","first-page":"69","article-title":"Ziconotide, a novel nonopioid analgesic, does not produce respiratory depression [abstract]","volume":"246","author":"Dean","year":"1999","journal-title":"J Neurol"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib6","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1021\/bi00382a004","article-title":"Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom","volume":"26","author":"Olivera","year":"1987","journal-title":"Biochemistry"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1146\/annurev.pa.35.040195.003423","article-title":"Antagonists of neuronal calcium channels: structure, function, and therapeutic implications","volume":"35","author":"Miljanich","year":"1995","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib8","unstructured":"Brose W, Pheifer B, Hassenbusch S et al. Analgesia produced by SNX-111 in patients with morphine resistant pain. Presented at the 15th Annual Meeting of the American Pain Society, November 1417, 1996, Washington, DC"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00002508-199709000-00012","article-title":"Use of intrathecal SNX-111, a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain","volume":"13","author":"Brose","year":"1997","journal-title":"Clin J Pain"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.291.1.63","article-title":"Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial","volume":"291","author":"Staats","year":"2004","journal-title":"JAMA"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib11","series-title":"Handbook of Pain Assessment, 2nd ed.","first-page":"659","article-title":"Assessment of pain and pain-related quality of life in clinical trials","author":"Dworkin","year":"2001"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0304-3959(83)90143-4","article-title":"Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases","volume":"17","author":"Daut","year":"1983","journal-title":"Pain"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib13","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singapore"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(75)90044-5","article-title":"The McGill Pain Questionnaire: major properties and scoring methods","volume":"1","author":"Melzack","year":"1975","journal-title":"Pain"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib15","series-title":"Goodman and Gilman\u2019s the Pharmacological Basis of Therapeutics, 9th ed.","first-page":"521","article-title":"Opioid analgesics and antagonists","author":"Reisine","year":"1996"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib16","series-title":"Neuropsychological Assessment, 3rd ed.","author":"Lezak","year":"1995"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2466\/pms.1958.8.3.271","article-title":"Validity of the Trail Making test as an indicator of organic brain damage","volume":"8","author":"Reitan","year":"1958","journal-title":"Percept Mot Skills"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/1097-4679(198707)43:4<402::AID-JCLP2270430411>3.0.CO;2-E","article-title":"Relationships between parts A and B of the Trail Making test","volume":"43","author":"Corrigan","year":"1987","journal-title":"J Clin Psychol"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/0006-8993(94)90398-0","article-title":"Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega conopeptide MVIIC)","volume":"653","author":"Gohil","year":"1994","journal-title":"Brain Res"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib20","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/0091270003253349","article-title":"Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients","volume":"43","author":"Wermeling","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib21","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0196-9781(00)00175-3","article-title":"Bioavailability of ziconotide in brain. influx from blood, stability, and diffusion","volume":"21","author":"Newcomb","year":"2000","journal-title":"Peptides"},{"key":"10.1111\/j.1525-1403.2006.00055.x_bib22","series-title":"PRIALT\u00ae (ziconotide intrathecal infusion) [package insert]","year":"2004"}],"container-title":["Neuromodulation: Technology at the Neural Interface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1525-1403.2006.00055.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094715911602559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094715911602559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1525-1403.2006.00055.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:48:53Z","timestamp":1761083333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094715911602559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S1094715911602559"],"URL":"https:\/\/doi.org\/10.1111\/j.1525-1403.2006.00055.x","relation":{},"ISSN":["1094-7159"],"issn-type":[{"value":"1094-7159","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intrathecal Ziconotide in the Treatment of Chronic Nonmalignant Pain: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Neuromodulation: Technology at the Neural Interface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1525-1403.2006.00055.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 International Neuromodulation Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}